Creation of apolipoprotein C-II (ApoC-II) mutant mice and correction of their hypertriglyceridemia with an ApoC-II mimetic peptides

Journal of Pharmacology and Experimental Therapeutics

Volumn 356, Issue 2, 2016, Pages 341-353

  Sakurai, Toshihiro ^a   Sakurai, Akiko ^a   Vaisman, Boris L ^a   Amar, Marcelo J ^a   Liu, Chengyu ^a   Gordon, Scott M ^a   Drake, Steven K ^b   Pryor, Milton ^a   Sampson, Maureen L ^b   Yang, Ling ^a   Freeman, Lita A ^a   Remaley, Alan T ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING LIPID METABOLISM; APOLIPOPROTEIN C2 A; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; APOLIPOPROTEIN C2; BIOMIMETIC MATERIAL; PEPTIDE FRAGMENT;

AMINO ACID SUBSTITUTION; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA SEQUENCE; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HYPERTRIGLYCERIDEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPOLYSIS; LIPOPROTEIN SYNTHESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; AMINO ACID SEQUENCE; ANIMAL; BLOOD; C57BL MOUSE; GENETICS; HYPERLIPOPROTEINEMIA TYPE 1; MALE; METABOLISM; MOLECULAR GENETICS; MUTATION; PREGNANCY;

AMINO ACID SEQUENCE; ANIMALS; APOLIPOPROTEIN C-II; BIOMIMETIC MATERIALS; FEMALE; HYPERLIPOPROTEINEMIA TYPE I; HYPERTRIGLYCERIDEMIA; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PREGNANCY; TRIGLYCERIDES;

EID: 84959440339     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.229740     Document Type: Article

References (60)

1. Amar MJA, D'Souza W, Turner S, Demosky S, Sviridov D, Stonik J, Luchoomun J, Voogt J, Hellerstein M, and Sviridov D, et al. (2010) 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice. J Pharmacol Exp Ther 334: 634-641.
2. Amar MJA, Sakurai T, Sakurai-Ikuta A, Sviridov D, Freeman L, Ahsan L, and Remaley AT (2015) A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice. J Pharmacol Exp Ther 352: 227-235.
3. Anantharamaiah GM, Jones JL, Brouillette CG, Schmidt CF, Chung BH, Hughes TA, Bhown AS, and Segrest JP (1985) Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 260: 10248-10255.
4. Athyros VG, Giouleme OI, Nikolaidis NL, Vasiliadis TV, Bouloukos VI, Kontopoulos AG, and Eugenidis NP (2002) Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 34: 472-475.
5. Auclair SM, Bhanu MK, and Kendall DA (2012) Signal peptidase I: Cleaving the way to mature proteins. Protein Sci 21: 13-25.
6. Beigneux AP, Davies BSJ, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, and Wong JS, et al. (2007) Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 5: 279-291.
7. Benlian P, Foubert L, Gagné E, Bernard L, De Gennes JL, Langlois S, Robinson W, and Hayden M (1996) Complete paternal isodisomy for chromosome 8 unmasked by lipoprotein lipase deficiency. Am J Hum Genet 59: 431-436.
8. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, and Rader DJ (2008) Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49: 1344-1352.
9. Boisfer E, Lambert G, Atger V, Tran NQ, Pastier D, Benetollo C, Trottier JF, Beaucamps I, Antonucci M, and Laplaud M, et al. (1999) Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J Biol Chem 274: 11564-11572.
10. Boullart ACI, de Graaf J, and Stalenhoef AF (2012) Serum triglycerides and risk of cardiovascular disease. Biochim Biophys Acta 1821: 867-875.
11. Breckenridge WC, Little JA, Steiner G, Chow A, and Poapst M (1978) Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 298: 1265-1273.
12. Brewer HB, Jr (1999) Hypertriglyceridemia: Changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 83 (9B): 3F-12F.
13. Brown WV, Levy RI, and Fredrickson DS (1970) Further characterization of apolipoproteins from the human plasma very low density lipoproteins. J Biol Chem 245: 6588-6594.
14. Carbery ID, Ji D, Harrington A, Brown V, Weinstein EJ, Liaw L, and Cui X (2010) Targeted genome modification in mice using zinc-finger nucleases. Genetics 186: 451-459.
15. Choo KH and Ranganathan S (2008) Flanking signal and mature peptide residues influence signal peptide cleavage. BMC Bioinformatics 9 (Suppl 12): S15.
16. Chung BH, Anatharamaiah GM, Brouillette CG, Nishida T, and Segrest JP (1985) Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. J Biol Chem 260: 10256-10262.
17. Connelly PW, Maguire GF, and Little JA (1987) Apolipoprotein CIISt. Michael. Familial apolipoprotein CII deficiency associated with premature vascular disease. J Clin Invest 80: 1597-1606.
18. Cui X, Ji D, Fisher DA, Wu Y, Briner DM, and Weinstein EJ (2011) Targeted integration in rat and mouse embryos with zinc-finger nucleases. Nat Biotechnol 29: 64-67.
19. Dumon MF and Clerc M (1986) Preliminary report on a case of apolipoproteins CI and CII deficiency. Clin Chim Acta 157: 239-248.
20. Eisenberg S, Gavish D, Oschry Y, Fainaru M, and Deckelbaum RJ (1984) Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J Clin Invest 74: 470-482.
21. Freeman LA (2013) Western blots. Methods Mol Biol 1027: 369-385.
22. Garelnabi M, Lor K, Jin J, Chai F, and Santanam N (2013) The paradox of ApoA5 modulation of triglycerides: Evidence from clinical and basic research. Clin Biochem 46: 12-19.
23. Goldberg IJ, Eckel RH, and Abumrad NA (2009) Regulation of fatty acid uptake into tissues: Lipoprotein lipase- and CD36-mediated pathways. J Lipid Res 50 (Suppl): S86-S90.
24. Gordon SM, Deng J, Lu LJ, and Davidson WS (2010) Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 9: 5239-5249.
25. Guilherme A, Virbasius JV, Puri V, and Czech MP (2008) Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9: 367-377.
26. Harrington JM, Nishanova T, Pena SR, Hess M, Scelsi CL, Widener J, and Hajduk SL (2014) A retained secretory signal peptide mediates high density lipoprotein (HDL) assembly and function of haptoglobin-related protein. J Biol Chem 289: 24811-24820.
27. Hiller K, Grote A, Scheer M, Münch R, and Jahn D (2004) PrediSi: Prediction of signal peptides and their cleavage positions. Nucleic Acids Res 32: W375-379.
28. Hoffer MJV, van Eck MM, Havekes LM, Hofker MH, and Frants RR (1993) Structure and expression of the mouse apolipoprotein C2 gene. Genomics 17: 45-51.
29. van der Hoogt CC, Berbée JF, Espirito Santo SM, Gerritsen G, Krom YD, van der Zee A, Havekes LM, van Dijk KW, and Rensen PC (2006) Apolipoprotein CI causes hypertriglyceridemia independent of the very-low-density lipoprotein receptor and apolipoprotein CIII in mice. Biochim Biophys Acta 1761: 213-220.
30. Ishihara M, Kujiraoka T, Iwasaki T, Nagano M, Takano M, Ishii J, Tsuji M, Ide H, Miller IP, and Miller NE, et al. (2005) A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46: 2015-2022.
31. Ito Y, Azrolan N, O'Connell A, Walsh A, and Breslow JL (1990) Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249: 790-793.
32. Jarjanazi H, Savas S, Pabalan N, Dennis JW, and Ozcelik H (2008) Biological implications of SNPs in signal peptide domains of human proteins. Proteins 70: 394-403.
33. Johansen CT, Kathiresan S, and Hegele RA (2011) Genetic determinants of plasma triglycerides. J Lipid Res 52: 189-206.
34. Kamp F, Guo W, Souto R, Pilch PF, Corkey BE, and Hamilton JA (2003) Rapid flipflop of oleic acid across the plasma membrane of adipocytes. J Biol Chem 278: 7988-7995.
35. Karpe F, Johansson J, and Carlson LA (1990) Studies on the lecithin: Cholesterol acyltransferase substrate properties of HDL as determined by its subclass distribution analysed by gradient gel electrophoresis. Biochim Biophys Acta 1042: 310-314.
36. LaRosa JC, Levy RI, Herbert P, Lux SE, and Fredrickson DS (1970) A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun 41: 57-62.
37. LeRoith D, Taylor SI, and Olefsky JM (2003) Diabetes mellitus: A fundamental and clinical text, Ed. 3rd, pp 169-170, Lippincott, Philadelphia.
38. Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H, Chen Y, Gucek M, Zhu J, and Cao H (2015) A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab 21: 455-467.
39. Liu C, Gates KP, Fang L, Amar MJ, Schneider DA, Geng H, Huang W, Kim J, Pattison J, and Zhang J, et al. (2015) Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia. Dis Model Mech 8: 989-998.
40. Liu C, Xie W, Gui C, and Du Y (2013) Pronuclear microinjection and oviduct transfer procedures for transgenic mouse production. Methods Mol Biol 1027: 217-232.
41. McIlhargey TL, Yang Y, Wong H, and Hill JS (2003) Identification of a lipoprotein lipase cofactor-binding site by chemical cross-linking and transfer of apolipoprotein C-II-responsive lipolysis from lipoprotein lipase to hepatic lipase. J Biol Chem 278: 23027-23035.
42. Nesvizhskii AI, Keller A, Kolker E, and Aebersold R (2003) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75: 4646-4658.
43. Nordestgaard BG, Benn M, Schnohr P, and Tybjaerg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298: 299-308.
44. Nordestgaard BG and Varbo A (2014) Triglycerides and cardiovascular disease. Lancet 384: 626-635.
45. Rashid S, Watanabe T, Sakaue T, and Lewis GF (2003) Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: The combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 36: 421-429.
46. Rousset X, Vaisman B, Auerbach B, Krause BR, Homan R, Stonik J, Csako G, Shamburek R, and Remaley AT (2010) Effect of recombinant human lecithin cholesterol acyltransferase infusion on lipoprotein metabolism in mice. J Pharmacol Exp Ther 335: 140-148.
47. Shachter NS, Hayek T, Leff T, Smith JD, Rosenberg DW, Walsh A, Ramakrishnan R, Goldberg IJ, Ginsberg HN, and Breslow JL (1994) Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest 93: 1683-1690.
48. Sharpe CR, Sidoli A, Shelley CS, Lucero MA, Shoulders CC, and Baralle FE (1984) Human apolipoproteins AI, AII, CII and CIII. cDNA sequences and mRNA abundance. Nucleic Acids Res 12: 3917-3932.
49. Sorenson RC, Bisgaier CL, Aviram M, Hsu C, Billecke S, and La Du BN (1999) Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids : Apolipoprotein A-I stabilizes activity. Arterioscler Thromb Vasc Biol 19: 2214-2225.
50. Symoens S, Malfait F, Renard M, André J, Hausser I, Loeys B, Coucke P, and De Paepe A (2009) COL5A1 signal peptide mutations interfere with protein secretion and cause classic Ehlers-Danlos syndrome. Hum Mutat 30: E395-E403.
51. Thorngate FE, Yancey PG, Kellner-Weibel G, Rudel LL, Rothblat GH, and Williams DL (2003) Testing the role of apoA-I, HDL, and cholesterol efflux in the atheroprotective action of low-level apoE expression. J Lipid Res 44: 2331-2338.
52. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, and Gelrud A (2009) Hypertriglyceridemic pancreatitis: Presentation and management. Am J Gastroenterol 104: 984-991.
53. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, Rothblat GH, Lund-Katz S, and Phillips MC (2007) Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 282: 25123-25130.
54. Vu TT, Zhou J, Leslie BA, Stafford AR, Fredenburgh JC, Ni R, Qiao S, Vaezzadeh N, Jahnen-Dechent W, and Monia BP, et al. (2015) Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. Blood 125: 2712-2719.
55. Wang CS (1991) Structure and functional properties of apolipoprotein C-II. Prog Lipid Res 30: 253-258.
56. Weinstock PH, Bisgaier CL, Aalto-Setälä K, Radner H, Ramakrishnan R, Levak- Frank S, Essenburg AD, Zechner R, and Breslow JL (1995) Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J Clin Invest 96: 2555-2568.
57. Wilson CJ, Priore Oliva C, Maggi F, Catapano AL, and Calandra S (2003) Apolipoprotein C-II deficiency presenting as a lipid encephalopathy in infancy. Ann Neurol 53: 807-810.
58. van de Woestijne AP, Monajemi H, Kalkhoven E, and Visseren FL (2011) Adipose tissue dysfunction and hypertriglyceridemia: Mechanisms and management. Obes Rev 12: 829-840.
59. Xu N and Dahlbäck B (1999) A novel human apolipoprotein (apoM). J Biol Chem 274: 31286-31290.
60. Zdunek J, Martinez GV, Schleucher J, Lycksell PO, Yin Y, Nilsson S, Shen Y, Olivecrona G, and Wijmenga S (2003) Global structure and dynamics of human apolipoprotein CII in complex with micelles: Evidence for increased mobility of the helix involved in the activation of lipoprotein lipase. Biochemistry 42: 1872-1889.